Research overview
CJC-1295 with DAC is listed separately from the no-DAC product in this catalogue. The distinction matters when locating the literature and selecting a research comparator. A similar name does not make two molecular forms interchangeable. This page provides a starting reference for the long-acting analogue and highlights the identity questions that should be resolved before an experimental comparison.
What the referenced research shows
Early randomized human studies — long-acting CJC-1295 analogue
Teichman and colleagues reported two randomized studies of the long-acting GHRH analogue CJC-1295 in healthy adults in 2006. Their outcomes included growth hormone, IGF-I and pharmacokinetic measurements. The findings refer to that investigated compound and protocol. They should not be transferred to a no-DAC material or used to infer the clinical safety, effectiveness or identity of a catalogue vial.
Reference: Teichman et al., 2006 — long-acting CJC-1295 in healthy adults ↗
Identity and comparison notes
Check explicitly for the DAC designation when comparing CJC-1295 listings and documents. No-DAC terminology is commonly associated with modified GRF products, but the exact identity must still be confirmed. Neither a shared category nor a similar product name is sufficient evidence that two preparations match the compound used in a paper.
Questions to ask about this batch
Match the selected DAC specification, SKU and supplied lot to its analytical documentation. Ask for the stated molecular form and identity method before interpreting the purity result. If a report belongs to a no-DAC specification or a combination product, it should not be used as evidence for this single-compound DAC listing.